SCHEMBL10147434

SCHEMBL10147434

CCOC(=O)c1cnc(-c2ccc(C)cc2C)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.60
DBF4 Q9UBU7 1/20 0.60
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 4/20 0.43
PKM P14618 1/20 0.43
TP53 P04637 3/20 0.41
HPGD P15428 3/20 0.41
GABRP O00591 2/20 0.41
GABRD O14764 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB1 P18505 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
GABRB2 P47870 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083303 0.88 CDC7 (0.59) CDC7DBF4MAPTKDM4EALDH1A1
SCHEMBL11698155 0.88 CDC7 (0.59) CDC7DBF4MAPTKDM4EALDH1A1
SCHEMBL23146170 0.84 CDC7 (0.63) CDC7DBF4MAPTLMNAKDM4E
SCHEMBL28711748 0.83 CDC7 (0.58) CDC7DBF4MAPTLMNAKDM4E
SCHEMBL23794795 0.81 CDC7 (0.79) CDC7DBF4MAPTLMNAKDM4E
SCHEMBL28595774 0.80 CDC7 (0.69) CDC7DBF4LMNAALDH1A1HPGD
SCHEMBL23794647 0.80 CDC7 (0.61) CDC7DBF4MAPTLMNAKDM4E
SCHEMBL25413995 0.80 CDC7 (0.57) CDC7DBF4MAPTLMNAKDM4E
SCHEMBL23794663 0.79 CDC7 (0.67) CDC7DBF4MAPTKDM4EALDH1A1
SCHEMBL6487827 0.77 CDC7 (0.61) CDC7DBF4LMNAKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P CDC7 1882/4885DBF4 664/4885MAPT 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.